Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.
Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.
Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.
BeyondSpring is scheduled to present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:00 am ET. Interested parties can access the presentation through a live webcast. BeyondSpring focuses on developing innovative cancer therapies, with their lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and enhancing cancer treatment outcomes. A replay of the presentation will be available post-event on their investor relations page.
BeyondSpring announced positive preliminary results from a Phase 1 trial of plinabulin combined with nivolumab and ipilimumab for treating small cell lung cancer (SCLC). The study showed a favorable 46% objective response rate (ORR) among 13 evaluable patients with resistant tumors. The combination also re-sensitized tumors previously treated with PD-1/PD-L1 inhibitors, achieving a 43% ORR.
The trial highlighted the treatment's safety with no Grade 4 events reported, and only 12.5% experiencing Grade 3/4 immune-related adverse events (IR-AEs), signaling potential for further development.
BeyondSpring Inc. (NASDAQ: BYSI) announced that CEO Dr. Lan Huang will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 8:00 am ET. The event will include opportunities for 1x1 meetings. The presentation can be accessed via webcast and will be available for replay on BeyondSpring's investor section afterward. BeyondSpring focuses on innovative cancer therapies, with its lead asset, plinabulin, in pivotal studies for cancer treatment and prevention of chemotherapy-induced neutropenia in the U.S. and China.
BeyondSpring, a biopharmaceutical company, filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC on April 30, 2021. The report includes audited financial statements and is accessible via the SEC's website and BeyondSpring's site under the Investors section. BeyondSpring focuses on developing innovative cancer therapies, primarily its lead asset plinabulin, aimed at preventing chemotherapy-induced neutropenia and studying its effects in non-small cell lung cancer. Shareholders can request a hard copy of the report free of charge.
BeyondSpring, a biopharmaceutical company focused on innovative cancer therapies, reported its 2020 financial results and recent milestones. The company completed NDAs for plinabulin in the U.S. and China for preventing chemotherapy-induced neutropenia, leveraging positive Phase 3 trial data. BeyondSpring secured $86.3 million in equity financing, ending 2020 with $109.5 million in cash. R&D expenses rose to $41.8 million while G&A expenses increased to $22.6 million, leading to a net loss of $61 million. Positive Phase 3 survival data for NSCLC is anticipated in mid-2021.
BeyondSpring (NASDAQ: BYSI) has announced five key presentations at the ASCO Annual Meeting, focusing on plinabulin, its lead cancer therapy. The presentations will highlight clinically significant improvements, including the reduction of febrile neutropenia and hospitalization rates in patients undergoing chemotherapy. Notably, plinabulin's combination with checkpoint inhibitors targeting small cell lung cancer will also be discussed. BeyondSpring aims to demonstrate plinabulin's unique capabilities in enhancing patient outcomes as it seeks to bring the drug to market in 2022.
BeyondSpring Inc. (NASDAQ: BYSI) will report its financial results for the year and quarter ending December 31, 2020, on April 30, 2021. A conference call is scheduled for 8:30 AM ET on the same day to discuss these results and provide a corporate update. BeyondSpring focuses on developing innovative cancer therapies, with its lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and currently under NDA review in the US and China. The company also has a pivotal study in non-small cell lung cancer and various immuno-oncology assets in its pipeline.
BeyondSpring has submitted a New Drug Application (NDA) to the FDA and China NMPA for plinabulin in combination with G-CSF to prevent chemotherapy-induced neutropenia (CIN). This innovative approach addresses a significant unmet medical need, as CIN represents a major complication in cancer treatment. The PROTECTIVE-2 Phase 3 study showed that plinabulin plus G-CSF improved grade 4 neutropenia prevention from 13.6% to 31.5%. The NDA is supported by data from five trials involving over 1,200 patients, indicating potential to enhance patient care and outcomes in oncology.
BeyondSpring (BYSI) announced a KOL webinar on March 18, 2021, focusing on Plinabulin, its lead asset aimed at preventing chemotherapy-induced neutropenia (CIN). Experts Douglas Blayney and Jeffrey Vacirca will present, detailing the unmet medical needs in CIN prevention. The update includes recent progression in Plinabulin's clinical trials, with positive topline data from the PROTECTIVE-2 Phase 3 trial. Currently, Plinabulin is also in the DUBLIN-3 trial for non-small cell lung cancer, with results expected in H2 2021, highlighting its potential dual functionality in oncology.
BeyondSpring, a biopharmaceutical company focused on innovative cancer therapies, announced CEO Dr. Lan Huang's virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. ET. The company will also hold one-on-one meetings during the LifeSci Advisors Corporate Access Event from January 7-13, 2021. BeyondSpring's lead asset, plinabulin, is in Phase 3 trials for non-small cell lung cancer and is recognized by the U.S. FDA as a Breakthrough Therapy for preventing chemotherapy-induced neutropenia.
